glp-1 patient education Kit for Dietitians | Editable Canva Handouts | Semaglutide Sarcopenia Client Resources | Medical Weight Loss Dietitians boost GLP-1 therapy success

Women often see more distributed fat loss, with changes in arms, legs, and hips as well as the midsection

Tang, H

Your provider has a clinical reason for the timing of your titration

If passed, TROA would: Permanently allow Medicare Part D to cover FDA-approved anti-obesity medications Expand Medicare Part B coverage of intensive behavioral therapy for obesity to include a wider range of providers (not just primary care physicians) However, in April 2025, CMS announced it would not include Medicare Part D coverage of obesity drugs in its rule changes for 2026, stating the proposal was "not appropriate at this time." That decision pushed the issue back to Congress, where the TROA remains under consideration

Conversely, point estimates for tirzepatide showed a potential modest advantage for heart failure endpoints, with CIs compatible with no difference, consistent with recent data supporting protective effects of semaglutide and tirzepatide on heart failure outcomes and a potential incremental benefit with the latter 22